MWNA
CRSP icon

Marshall Wace North America’s CRISPR Therapeutics CRSP Stock Holding History

Marshall Wace North America’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-68,335
Closed -$10.5M – 1553
2020
Q4 		$10.5M Buy
+68,335
New +$8.08M 0.05% 369
2019
Q3 		– Sell
-4,945
Closed -$233K – 1342
2019
Q2 		$233K Buy
+4,945
New +$198K ﹤0.01% 1015
2018
Q2 		– Sell
-476,762
Closed -$21.8M – 1434
2018
Q1 		$21.8M Buy
+476,762
New +$19.7M 0.11% 216

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Marshall Wace North America's CRSP Position: Q1 2021 in Review

Marshall Wace North America sold out of CRISPR Therapeutics (CRSP) in Q1 2021, closing a stake of 68,335 shares — an estimated $10.5M sold.

Marshall Wace North America first reported a position in CRSP in Q1 2018 and held it in 3 quarters. The position peaked at $21.8M in Q1 2018. 443 funds tracked by Wall St. Rank hold CRSP as of Q1 2021.

  • Marshall Wace North America reported no remaining CRISPR Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Marshall Wace North America sold 68,335 CRISPR Therapeutics shares in Q1 2021, an estimated $10.5M.
  • Marshall Wace North America first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 3 quarters.
  • Marshall Wace North America's CRISPR Therapeutics position peaked at $21.8M in Q1 2018.
  • 443 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.